70 completed, 2 recruiting, 2 unknown, 1 terminated. 64 Phase 1, 6 Not applicable, 3 Phase 2, 3 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 64 | Completed 60, Unknown 2, Recruiting 1, Withdrawn 1 |
| Not applicable | 6 | Completed 5, Recruiting 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow Treatment B: new trials by email Literature Review of Treatment B trials Research Report on Treatment B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Improving Speech in Noise Using Noninvasive Stimulation Cymba Conchae stimulation, Earlobe stimulation - Traumatic Brain Injury, Hearing Loss | Not applicable | Recruiting | University of Florida | 55 | 2026-03-21 | 2026-03-27 |
| A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant in Healthy Female Participants Treatment A, Treatment B, Treatment C - Vasomotor Symptoms | Phase 1 | Completed | Bayer | 18 | 2025-11-05 | 2026-01-27 |
| A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers treatment A, treatment B, treatment C - Dyslipidemia | Phase 1 | Recruiting | Korea United Pharm. Inc. | 50 | 2025-08-12 | 2025-09-09 |
| A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Withdrawn | Pfizer | 2025-04-28 | 2025-04-24 | |
| A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults Treatment B, Treatment A - SARS-CoV-2 Infections | Phase 1 | Completed | Pfizer | 20 | 2024-11-22 | 2025-01-24 |
| A Study to Assess the Abuse Potential of Intranasal Cebranopadol Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug - Abuse, Drug | Phase 1 | Completed | Tris Pharma, Inc. | 48 | 2024-06-28 | 2025-12-18 |
| A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib Treatment A, Treatment B - Healthy Adults | Phase 1 | Completed | Mirati Therapeutics Inc. | 18 | 2023-06-01 | 2024-03-13 |
| Electrophysiological Effects of Potential QT Prolonging Drugs Clarithromycin, Pimozide, Placebo (Part 1) - Drug-induced QT Prolongation, Pharmacokinetics | Phase 1 | Completed | Food and Drug Administration (FDA) | 44 | 2023-03-21 | 2023-06-22 |
| Relative Bioavailability of Evobrutinib Tablet Batches Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 28 | 2023-01-18 | 2025-12-23 |
| Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics Treatment A, Treatment B, Treatment C - Healthy Adult Participants | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 42 | 2022-10-13 | 2025-02-14 |
| A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets - Biological Availability | Phase 1 | Completed | Pfizer | 52 | 2022-08-24 | 2024-10-01 |
| P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release Treatment A, Treatment B, Treament C - Pharmacokinetics | Phase 2 | Completed | Rennes University Hospital | 27 | 2022-02-15 | 2024-12-11 |
| Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers Treatment A, Treatment B, Treatment C - Healthy Volunteers | Phase 1 | Completed | Novartis Pharmaceuticals | 33 | 2022-02-03 | 2022-12-28 |
| To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers Treatment A, Treatment B, Treatment C - Healthy | Phase 1 | Completed | JW Pharmaceutical | 40 | 2022-01-17 | 2022-07-19 |
| Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers Treatment A, Treatment B, Treatment C - Perennial Allergic Rhinitis, Rhinitis, Allergic | Not applicable | Completed | Altamira Medica Ltd. | 37 | 2021-11-10 | 2024-09-19 |
| Neuromodulation for Dysphoria Guided Meditation VR for Wellness, Accelerated Transcranial Magnetic Stimulation: MagVenture Transcranial Magnetic Stimulation (Treatment Coil Cool B70 AP), Accelerated Transcranial Magnetic Stimulation: MagVenture Transcranial Magnetic Stimulation (Cool D-B80 AP) - Dysphoria | Not applicable | Completed | Florida State University | 29 | 2021-09-29 | 2026-04-13 |
| Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers Treatment A, Treatment B, Treatment C - Heart Failure | Phase 1 | Completed | AstraZeneca | 20 | 2021-06-29 | 2021-09-09 |
| Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS) Crizotinib - Healthy Participants | Phase 1 | Completed | Pfizer | 25 | 2021-04-16 | 2022-01-20 |
| Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393 CKD-501, D759, D150, CKD-393 0.5/100/1000 mg - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Unknown | Chong Kun Dang Pharmaceutical | 26 | 2021-02-18 | 2021-01-12 |
| A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol Treatment A, Treatment B, Treatment C - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Completed | AstraZeneca | 47 | 2020-10-19 | 2023-01-23 |
Showing 20 of 76. Sign in to see all of them.
Arthritis, Rheumatoid (3) · Asthma (3) · Diabetes Mellitus, Type 2 (3) · Pulmonary Disease, Chronic Obstructive (3) · Dyslipidemias (2) · Heart Failure (2) · Hypertension (2) · Acute Kidney Injury (1) · Brain Injuries, Traumatic (1) · COVID-19 (1) · Cataract (1) · Coronary Artery Disease (1) · Diarrhea (1) · HIV Infections (1) · Hearing Loss (1)
Pfizer (16) · AstraZeneca (10) · Actavis Inc. (5) · Chong Kun Dang Pharmaceutical (3) · Chiesi Farmaceutici S.p.A. (2) · International Partnership for Microbicides, Inc. (2) · Tonix Pharmaceuticals, Inc. (2) · AJU Pharm Co., Ltd. (1) · Actelion (1) · Alexion Pharmaceuticals, Inc. (1) · Altamira Medica Ltd. (1) · Alvogen Korea (1) · Bayer (1) · Boehringer Ingelheim (1) · Corcept Therapeutics (1)
United States (25) · Singapore (10) · United Kingdom (8) · South Korea (6) · Canada (5) · Germany (5) · Belgium (3) · France (3) · Bulgaria (1) · Mexico (1) · Netherlands (1)
Daniel V. Freeland, DO (3) · Denis Audet, MD (2) · James P. Doherty, DO (2) · Rainard Fuhr, Dr. med. (2) · Alen Jambrecina (1) · Angela Eakin, MD (1) · Annelize Koch, Dr. (1) · Bojan Pajic, MD, PhD (1) · Chad McQueen, PharmD (1) · Choon Ok Kim, M.D., Ph.D. (1) · David Han, Dr. (1) · Don Kellerman, PharmD (1)
PMID 41920422, PMID 22535635, PMID 25642437, PMID 26318254, PMID 28011397, PMID 29496167, PMID 33834354, PMID 34817414, PMID 35170228, PMID 35410754, PMID 36264536, PMID 36670877, PMID 37607661, PMID 38780528, PMID 39498822, PMID 40224597, PMID 40307580
2018 (2), 2014 (1), 2019 (1)